Page 2 - Agonist News Today

The study in the International Journal of Obesity reports that cannabis and its derivatives may influence weight and waist circumference, with different effects on body fat, suggesting potential as a therapeutic aid in obesity management.

Researchers investigated the association between the timing of in-utero exposure to β2-agonists and corticosteroids and offspring neurodevelopmental milestones during the initial three years of life.

A research team from the UC Davis Comprehensive Cancer Center has identified a crucial epitope (a protein section that can activate the larger protein) on the CD95 receptor that can cause cells to die.

Persistent blocking of NMDAR and burst-type firing by lateral habenula (LHb) neurons may offer a basis for the long-lasting antidepressant effects of ketamine.

The study reveals a significant increase in the usage of GLP-1 receptor agonists, particularly Ozempic and Trulicity, for weight management and Type 2 diabetes in the U.S. from 2014 to 2022. Amidst rapid growth and shortages, the paper calls for evidence-based decision-making to ensure stable medication supply and effective treatment.

In a groundbreaking 84-week-long study, researchers found that tirzepatide, a medication initially designed for treating type 2 diabetes, significantly bolstered weight loss in overweight and obese patients already on intensive lifestyle programs. While the drug showed promise in further reducing body weight and improving cardiometabolic factors, mild to moderate gastrointestinal side effects were the most common drawback.

Researchers at Weill Cornell Medicine have discovered that radiation therapy combined with two types of immunotherapy-;one that boosts T cells, and another that boosts dendritic cells-;can control tumors in preclinical models of triple negative breast cancer, a cancer type that's typically resistant to immunotherapy alone.

Meta-analysis finds tirzepatide to be the most effective GLP-1 receptor agonist for glucose and weight control in type 2 diabetes patients. The study suggests tirzepatide could be preferable in initial stages of the disease, while other GLP-1 receptor agonists combined with insulin are equally effective for long-term diabetics.

Groundbreaking research published today in Nature Genetics describes the largest-ever study into the genetics of random "round-the-clock" blood glucose levels.

The study reveals that oral semaglutide, a medication primarily used for type 2 diabetes, effectively reduces body weight and blood glucose levels in diet-induced obese mice. The findings suggest that this drug could be a promising treatment for obesity and offer a suitable animal model for future research.